云顶新耀EVM14中美双获批10月13日,专注于创新疗法的发现、临床开发、生产和商业化的生物制药公司云顶新耀宣布,其肿瘤相关抗原(TAA)肿瘤疫苗EVM14的新药临床试验申请(IND)已获得NMPA的批准。EVM14成为公司首个实现国家药监局(NMPA)和美国食品药品监督管理局(FDA)IND双获批的mRNA肿瘤治疗性疫苗。截图来源:CDE官网公开资料显示,EVM14基于云顶新耀自主知识产权的...
Source Link云顶新耀EVM14中美双获批10月13日,专注于创新疗法的发现、临床开发、生产和商业化的生物制药公司云顶新耀宣布,其肿瘤相关抗原(TAA)肿瘤疫苗EVM14的新药临床试验申请(IND)已获得NMPA的批准。EVM14成为公司首个实现国家药监局(NMPA)和美国食品药品监督管理局(FDA)IND双获批的mRNA肿瘤治疗性疫苗。截图来源:CDE官网公开资料显示,EVM14基于云顶新耀自主知识产权的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.